"Plasma-based, tumor-informed MRD analysis may predict disease recurrence during adjuvant treatment and during posttreatment follow-up," the authors write. "MRD monitoring may inform clinical ...

The trial will also explore end of therapy ctDNA-MRD analysis as an exploratory endpoint. According to the company, the standard treatment for newly diagnosed advanced cHL patients currently ...

During a live event, Kathleen A. Dorritie, MD, discussed updated outcomes from the GRIFFIN and PERSEUS clinical trials of quadruplet therapy in multiple myeloma.

In an era marked by remarkable advancements in medical diagnostics, the global minimal residual disease (MRD) testing market is poised for unprecedented growth. Projections suggest that by 2031, the ...

In the near future, the Minimal Residual Disease (MRD) testing industry is poised to experience remarkable growth and ...

The North American minimal residual disease (MRD) testing market is poised for substantial growth in the coming years. With a projected annual increase of 11.1% throughout the forecast period, ...

Driven EcosystemsDublin, April 08, 2025 (GLOBE NEWSWIRE) -- The "Minimal Residual Disease Testing Market by Product Type (Instruments, Reagents & Kits, Software & Services), Test Techniques (Flow ...

As a result of such analysis, candidate markers can be ranked for their potential reliability for the MRD monitoring. In cases with clonotypes characterized by high-generation frequency ...

Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo"), a leader in the development of diagnostic and prognostic tests for human disease through the analysis of chromosomal ...

Roy S. Herbst, M.D., Ph.D., from Yale School of Medicine and Yale Cancer Center in New Haven, Connecticut, and colleagues examined whether tumor-informed, circulating tumor DNA-based MRD could predict ...